Marshfield Labs Discontinues EGFR Testing

Please note that effective Monday, February 1st, Marshfield Labs will discontinue EGFR testing by IHC due to poor correlation between EGFR expression by IHC and treatment response. Recently published guidelines from the National Comprehensive Cancer Network and the American Society of Clinical Oncology recommend KRAS mutation testing as part of the evaluation of metastatic colorectal cancer patients who are being considered for anti-EGFR therapy. Retrospective analyses of clinical trials have consistently demonstrated that patients with metastatic colorectal carcinoma and mutant KRAS are unlikely to benefit from the addition of cetuximab or panitumumab to a chemotherapy regimen. Testing for KRAS mutation in this setting is now recommended and marks a paradigm shift in the management of these patients.